Qsoowis Wart Remover

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the removal of common warts characterized by a rough, cauliflower-like appearance.

Limitations of Use: This drug is not intended for the treatment of warts located on the face, genitals, or mucous membranes.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the medication to ensure optimal results.

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area must be dried completely to ensure proper adhesion of the medication.

A small amount of the medication should be applied directly to cover each wart. It is important to allow the application to dry completely before proceeding with any additional activities.

This application should be repeated twice daily as needed, with a maximum treatment duration of up to 12 weeks. Regular monitoring of the treatment area is recommended to assess the effectiveness and any potential side effects.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated skin or reddened areas is not recommended due to the potential for exacerbating the condition. Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of adverse effects.

The product should not be applied to birthmarks, warts with hair growth, or moles, as these may present unique risks that could lead to complications.

Warnings and Precautions

For external use only; contact with the eyes should be strictly avoided. In the event of accidental exposure to the eyes, it is imperative to rinse thoroughly with water for at least 15 minutes to mitigate potential irritation or damage.

Inhalation of vapors should be avoided to prevent respiratory discomfort or adverse effects. Should ingestion occur, immediate medical assistance must be sought, or the individual should contact a Poison Control Center without delay.

If discomfort persists after application, it is advised to discontinue use and consult a healthcare professional for further evaluation and guidance.

Pregnant or breastfeeding individuals are strongly encouraged to seek advice from a qualified health professional prior to using this product to ensure safety for both the mother and child.

Side Effects

Patients should be aware that the product is intended for external use only and must be kept away from the eyes. In the event of contact with the eyes, it is recommended to rinse thoroughly with water for at least 15 minutes. Additionally, patients are advised to avoid inhaling vapors associated with the product.

In clinical practice, if discomfort persists after using the product, patients should discontinue use and consult a healthcare professional for further guidance. This precaution is essential to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Qsoowis Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, careful consideration and professional guidance are recommended for lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no information available regarding overdosage for this product. Healthcare professionals are advised to monitor patients closely for any adverse effects and to follow standard protocols for managing potential overdose situations. In the absence of specific data, it is recommended that clinicians exercise caution and consider supportive care as necessary. Should any symptoms arise, appropriate symptomatic treatment should be initiated based on the clinical presentation of the patient.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to fully evaluate the nonclinical toxicology profile.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed.

Patients should be informed to avoid using the product on irritated skin, reddened areas, or if they have diabetes or poor blood circulation. Additionally, it is important to discuss the use of the product on birthmarks, warts with hair growth, or moles, as these conditions may require special consideration.

Healthcare providers should instruct patients to stop using the product and consult a doctor if discomfort persists. Furthermore, patients who are pregnant or breastfeeding should be encouraged to consult a health professional before using the product to ensure safety for themselves and their child.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and efficacy. It should be stored at room temperature, away from direct light exposure. To maintain the product's quality, it is essential to keep the tube tightly closed when not in use. Additionally, the product must be discarded after opening to prevent any potential degradation or contamination.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a small amount to cover each wart, allowing it to dry. This application should be repeated twice daily as needed, for a duration of up to 12 weeks.

Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. Additionally, patients are instructed to discontinue use and seek medical advice if discomfort persists. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Qsoowis Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)